Prucalopride, a systemic enterokinetic, for the treatment of constipation.
about
Management of faecal incontinence and constipation in adults with central neurological diseasesManagement of faecal incontinence and constipation in adults with central neurological diseasesPrucalopride for the treatment of chronic constipationManagement of faecal incontinence and constipation in adults with central neurological diseasesSlow transit constipation: a review of a colonic functional disorderPatient considerations in the management of chronic constipation: focus on prucaloprideDisorders of gastrointestinal hypomotilityPrucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis.Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled TrialsPrucalopride: the evidence for its use in the treatment of chronic constipation.Prucalopride for constipation.Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipationSystematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersRandomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 studyThe treatment of irritable bowel syndromeCurrent management strategies and therapeutic targets in chronic constipation.Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study.Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation.Novel therapies in the treatment of irritable bowel syndrome.Chronic idiopathic slow transit constipation: pathophysiology and management.Pharmacology of serotonin: what a clinician should know.Prucalopride: safety, efficacy and potential applications.Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study.Chronic constipation in children: organic disorders are a major cause.A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptors.Prucalopride for the treatment of ileus.Treatments targeting putative mechanisms in irritable bowel syndrome.Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation.Drugs acting on serotonin receptors for the treatment of functional GI disorders.Drug development for the irritable bowel syndrome: current challenges and future perspectivesChallenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Management Strategies for Abdominal Bloating and Distension.Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.Investigational agents for the irritable bowel syndrome.Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.Delayed gastric emptying in Parkinson's disease.Prucalopride: a review of its use in the management of chronic constipation.New pharmacological treatment options for chronic constipation.
P2860
Q24201142-2A4E64FA-718F-4148-B735-2086BD619DFAQ24201722-A4233891-9B99-447F-8226-D7EBF2C92DBAQ24203815-3E804173-1A81-4AAD-BFFB-317FB440DD62Q24246359-E6282887-69F4-4BC9-849C-25A9A90C787EQ24653627-A831D815-9E93-4423-AACA-9979E9C14EF1Q26741304-30F4E2F4-F4E9-4A52-A4AD-91F5D7C0E4ACQ28070278-E9D05FA6-A2A3-43E5-9BDA-8A763A0F915DQ33461315-4E69E2A0-02BC-425E-B67E-F6EF6CD48256Q33467828-F28934A3-033D-4529-8112-FE14395D42A9Q33973983-3EDCB01B-1BFF-4D29-A921-22397F7DB247Q34094831-AF44787E-EEEF-4FD9-B113-D82DCB123C9FQ34146166-57B54752-4479-4FE4-9349-BFF91F2FE77DQ34166903-0A915F3A-6CAE-4B2D-9FF0-95A90B11621CQ34230555-6A40C357-5450-4491-91D9-B898E427BBC9Q34409009-17E3BA2C-8A05-4787-8F04-B3646440887DQ34565704-F011D060-A368-42B0-8C8F-AFB5018EA1CEQ34567186-DA550CFA-863A-4E95-B346-3C8AFC4A1686Q35026383-1F63D1B4-9490-4A5E-90E9-03C41DF51877Q35059682-047CBFD0-7B75-4414-9945-55862FAA6CC1Q35094684-1390214D-39BC-4A19-B012-31A1E76A6720Q35157513-1B4514D2-E261-4036-B6C5-3A2DB6617CA5Q35596862-BA6031B8-64AF-436F-839C-6F708DE8A46FQ35688594-B54EBA31-1FEC-44DB-93ED-9AF96D4DCACBQ35718568-34DC74E3-2924-4AFD-B47C-45F581924533Q36019991-E5CB3F04-A340-4197-AE5D-0FB7FDF1E687Q36052511-1BBC8500-AF71-4A93-947E-8C78D65C42A8Q36302121-EF399792-BA7D-4193-9528-00C01A5ED41AQ36304083-B12C1F9E-0B0C-454B-B6EB-A554B275A53CQ36321320-3D00AE8B-5F37-4809-9833-8D5D3CD6A7E0Q36478089-3DC12E05-AACF-4ABB-95ED-699E42C731EEQ36579818-332B41A9-FAFA-4135-A8D5-8B4D893E60CBQ37164063-5E729CAC-C842-4DF1-92B7-C4CFA58CE4C0Q37190545-E6A0AD91-EAD7-4932-9080-20BB9324F8AEQ37426287-3A8F6943-DF66-4356-9C2E-F1F372E6FC00Q37735172-B942898B-7C0D-4419-99E7-0DE72F9008A0Q37788218-EF2A895B-D36F-4D38-B805-1115927EBB8FQ37886156-1D009481-4C04-4B09-905C-ECFCA2F908A2Q38154857-BBB2C47A-9DDE-4EB2-84D0-0DA965E18F27Q38160205-EC392B7D-8DFF-4514-A067-F9F704D715C9Q38198743-852AB323-539C-4D62-825C-721ACD8BF38C
P2860
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
@en
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
@nl
type
label
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
@en
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
@nl
prefLabel
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
@en
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
@nl
P2093
P2860
P1476
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2036.2002.01272.X
P407
P577
2002-07-01T00:00:00Z